Immunome (NASDAQ:IMNM) Rating Reiterated by Wedbush

Immunome (NASDAQ:IMNM)‘s stock had its “outperform” rating restated by Wedbush in a research report issued to clients and investors on Friday, Benzinga reports. They currently have a $33.00 price objective on the stock. Wedbush’s target price would suggest a potential upside of 172.50% from the stock’s previous close.

Separately, Piper Sandler lowered their price objective on shares of Immunome from $27.00 to $23.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 13th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $29.00.

Immunome Price Performance

Immunome stock opened at $12.11 on Friday. The firm has a market cap of $727.21 million, a price-to-earnings ratio of -1.57 and a beta of 1.76. The firm has a fifty day moving average price of $13.93 and a two-hundred day moving average price of $14.26. Immunome has a fifty-two week low of $6.93 and a fifty-two week high of $30.96.

Immunome (NASDAQ:IMNM) last announced its earnings results on Monday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.11). The business had revenue of $2.36 million for the quarter, compared to the consensus estimate of $2.62 million. Immunome had a negative net margin of 2,435.02% and a negative return on equity of 38.19%. As a group, sell-side analysts expect that Immunome will post -1.92 earnings per share for the current year.

Insider Transactions at Immunome

In related news, insider Jack Higgins sold 3,524 shares of the company’s stock in a transaction dated Thursday, August 15th. The shares were sold at an average price of $13.93, for a total value of $49,089.32. Following the sale, the insider now owns 16,000 shares of the company’s stock, valued at $222,880. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, insider Jack Higgins sold 3,524 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $13.93, for a total transaction of $49,089.32. Following the completion of the transaction, the insider now owns 16,000 shares in the company, valued at $222,880. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Max Rosett sold 14,380 shares of the stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $16.01, for a total value of $230,223.80. Following the transaction, the chief financial officer now owns 47,476 shares of the company’s stock, valued at $760,090.76. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 8.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of IMNM. Redmile Group LLC increased its holdings in Immunome by 26.0% during the 1st quarter. Redmile Group LLC now owns 4,889,554 shares of the company’s stock valued at $120,674,000 after purchasing an additional 1,010,139 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Immunome by 113.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock worth $55,425,000 after buying an additional 1,194,451 shares in the last quarter. Vanguard Group Inc. grew its holdings in Immunome by 16.1% during the 1st quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock worth $49,847,000 after acquiring an additional 279,712 shares during the last quarter. Marshall Wace LLP increased its position in Immunome by 228.5% in the 2nd quarter. Marshall Wace LLP now owns 1,713,325 shares of the company’s stock valued at $20,731,000 after acquiring an additional 1,191,774 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in shares of Immunome by 10.6% in the first quarter. Janus Henderson Group PLC now owns 1,538,414 shares of the company’s stock worth $37,957,000 after acquiring an additional 146,943 shares during the last quarter. Institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.